Utility of Commercial Systems for Identification of Burkholderia cepacia Complex from Cystic Fibrosis Sputum Culture-Reference-Cited by-同舟云学术

Utility of Commercial Systems for Identification of Burkholderia cepacia Complex from Cystic Fibrosis Sputum Culture

Published:2000-08 Issue:8 Volume:38 Page:3112-3115
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Shelly Deborah Blecker¹,Spilker Theodore²,Gracely Edward J.³,Coenye Tom⁴,Vandamme Peter⁴,LiPuma John J.²

Affiliation:

1. Clinical Microbiology Laboratory, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 191041;

2. Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan 481092;

3. Department of Community and Preventive Medicine, MCP Hahnemann University, Philadelphia, Pennsylvania 191293; and

4. Laboratorium voor Microbiologie, Universiteit Gent, Ghent, Belgium4

Abstract

ABSTRACT Performances of several commercial test systems were reviewed to determine their relative levels of accuracy in identifying Burkholderia cepacia complex isolates recovered from cystic fibrosis sputum culture. Positive predictive values ranged from 71 to 98%; negative predictive values ranged from 50 to 82%. All systems misidentified B. cepacia complex. The species most frequently misidentified as B. cepacia was Burkholderia gladioli . These data support the results of previous studies that recommend confirmatory testing, including the use of DNA-based methods, for sputum culture isolates presumptively identified as B. cepacia .

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.38.8.3112-3115.2000

Reference14 articles.

1. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications;Burdge D. R.;Clin. Infect. Dis.,1995

2. Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources

3. Description of Pandoraea gen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensis comb. nov;Coenye T.;Int. J. Syst. Evol. Microbiol.,2000

4. Gilligan P. H. Pseudomonas and Burkholderia Manual of clinical microbiology 6th ed. Murray P. R. Baron E. J. Pfaller M. A. Tenover F. C. Yolken R. H. 1995 509 519 ASM Press Washington D.C.

5. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and mitigation strategies associated with Burkholderia cepacia complex contamination in pharmaceutical manufacturing;Archives of Microbiology;2024-03-14

2. Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections;Journal of the Pediatric Infectious Diseases Society;2022-09-01

3. Burkholderia in Transplant: Important to Speciate and Important to Treat;Emerging Transplant Infections;2021

4. A comparison of culture-based, real-time PCR, droplet digital PCR and flow cytometric methods for the detection of Burkholderia cepacia complex in nuclease-free water and antiseptics;Journal of Industrial Microbiology and Biotechnology;2020-07-01

5. Burkholderia in Transplant: Important to Speciate and Important to Treat;Emerging Transplant Infections;2020